Study 309/Keynote-775: A Randomized, Phase 3 Study to Compare the Efficacy and Safety of Lenvatinib with Pembrolizumab vs Treatment of Physician’s Choice in Advanced Endometrial Cancer

Description

Recorded Live: May 10, 2022

Presenter
Vicky Makker, MD
USA

Summary

Availability:

On-Demand

Cost:

FREE

Create Account

Recommended

Multidisciplinary Approach to Treating Advanced Endometrial Cancer

FREE

An Evolving Frontier: Endometrial Cancer Treatment

FREE

Immunotherapy and its impact on overall survival in patients with recurrent endometrial cancer

FREE

Endometrial Cancer Tumor Board: Matching the right therapy to the right patient

FREE

Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications

FREE

Surgery for Early Cervical Cancer: Current Key Aspects

Master Session held at IGCS 2023 in Seoul.

FREE

IGCS 2024 Endometrial Cancer Master Session

FREE

Journal Club: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

FREE

IGCS 2024 Cervical Master Sessions: Moving Forwards

FREE

Redefining Platinum Sensitivity : Additional Treatment Considerations in a Changing Paradigm

FREE